Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(6.87) per share which missed the analyst consensus estimate of $(4.13) by 66.34 percent. This is a 115.36 percent decrease over losses of $(3.19) per share from the same period last year. The company reported quarterly sales of $9.389 million which beat the analyst consensus estimate of $9.090 million by 3.29 percent.